These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 33846715)

  • 21. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume.
    Lujan ME; Jarrett BY; Brooks ED; Reines JK; Peppin AK; Muhn N; Haider E; Pierson RA; Chizen DR
    Hum Reprod; 2013 May; 28(5):1361-8. PubMed ID: 23503943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study.
    West S; Lashen H; Bloigu A; Franks S; Puukka K; Ruokonen A; Järvelin MR; Tapanainen JS; Morin-Papunen L
    Hum Reprod; 2014 Oct; 29(10):2339-51. PubMed ID: 25085801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
    Alebić MŠ; Stojanović N; Duhamel A; Dewailly D
    Hum Reprod; 2015 Aug; 30(8):1927-33. PubMed ID: 26048913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychometric properties of the Iranian version of modified polycystic ovary syndrome health-related quality-of-life questionnaire.
    Bazarganipour F; Ziaei S; Montazeri A; Faghihzadeh S; Frozanfard F
    Hum Reprod; 2012 Sep; 27(9):2729-36. PubMed ID: 22740491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of long-term exogenous testosterone administration on ovarian morphology, determined by transvaginal (3D) ultrasound in female-to-male transsexuals.
    Caanen MR; Schouten NE; Kuijper EAM; van Rijswijk J; van den Berg MH; van Dulmen-den Broeder E; Overbeek A; van Leeuwen FE; van Trotsenburg M; Lambalk CB
    Hum Reprod; 2017 Jul; 32(7):1457-1464. PubMed ID: 28505246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
    Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
    Fertil Steril; 2018 Aug; 110(3):364-379. PubMed ID: 30033227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
    Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
    Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicians' perspectives on diagnosing polycystic ovary syndrome in Australia: a qualitative study.
    Copp T; Muscat DM; Hersch J; McCaffery KJ; Doust J; Mol BW; Dokras A; Jansen J
    Hum Reprod; 2020 Mar; 35(3):660-668. PubMed ID: 32101283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.
    Stepto NK; Cassar S; Joham AE; Hutchison SK; Harrison CL; Goldstein RF; Teede HJ
    Hum Reprod; 2013 Mar; 28(3):777-84. PubMed ID: 23315061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adolescents diagnosed with polycystic ovary syndrome under the Rotterdam criteria but not meeting the diagnosis under the updated guideline.
    Kim JJ; Hwang KR; Lee D; Kim S; Choi YM
    Hum Reprod; 2024 May; 39(5):1072-1077. PubMed ID: 38514450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnostic performance of antimullerian hormone for polycystic ovarian syndrome and polycystic ovarian morphology.
    Vural F; Vural B; Kardaş E; Ertürk Coşkun AD; Yildirim İ
    Arch Gynecol Obstet; 2023 Apr; 307(4):1083-1090. PubMed ID: 36565362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
    Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
    JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of PCOS and related hyperandrogenic traits in premenopausal women with type 1 diabetes: a systematic review and meta-analysis.
    Bayona A; Martínez-Vaello V; Zamora J; Nattero-Chávez L; Luque-Ramírez M; Escobar-Morreale HF
    Hum Reprod Update; 2022 Jun; 28(4):501-517. PubMed ID: 35237802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation.
    Mostinckx L; Segers I; Belva F; Buyl R; Santos-Ribeiro S; Blockeel C; Smitz J; Anckaert E; Tournaye H; De Vos M
    Hum Reprod; 2019 Aug; 34(8):1595-1607. PubMed ID: 31347678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.
    Dewailly D; Lujan ME; Carmina E; Cedars MI; Laven J; Norman RJ; Escobar-Morreale HF
    Hum Reprod Update; 2014; 20(3):334-52. PubMed ID: 24345633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome.
    Romero-Ruiz A; Skorupskaite K; Gaytan F; Torres E; Perdices-Lopez C; Mannaerts BM; Qi S; Leon S; Manfredi-Lozano M; Lopez-Rodriguez C; Avendaño MS; Sanchez-Garrido MA; Vazquez MJ; Pinilla L; van Duin M; Kohout TA; Anderson RA; Tena-Sempere M
    Hum Reprod; 2019 Dec; 34(12):2495-2512. PubMed ID: 31820802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.
    Ezeh U; Pisarska MD; Azziz R
    Hum Reprod; 2022 Mar; 37(3):553-564. PubMed ID: 35048126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevation of markers of endotoxemia in women with polycystic ovary syndrome.
    Banaszewska B; Siakowska M; Chudzicka-Strugala I; Chang RJ; Pawelczyk L; Zwozdziak B; Spaczynski R; Duleba AJ
    Hum Reprod; 2020 Oct; 35(10):2303-2311. PubMed ID: 32869098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
    Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
    Hum Reprod; 2018 Sep; 33(9):1602-1618. PubMed ID: 30052961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study.
    Pinola P; Lashen H; Bloigu A; Puukka K; Ulmanen M; Ruokonen A; Martikainen H; Pouta A; Franks S; Hartikainen AL; Järvelin MR; Morin-Papunen L
    Hum Reprod; 2012 Nov; 27(11):3279-86. PubMed ID: 22933528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.